

Humana

Healthy Horizons®
in Louisiana

<u>Notification:</u>	HUM 7805
<u>Category:</u>	HCPCS - Drugs & Biologicals
<u>Topic:</u>	Louisiana Medicaid: fam-trastuzumab deruxtecan – HCPCS code J9358
<u>What is changing? / Change Description:</u>	<p>For a diagnosis of any of the following:</p> <ul style="list-style-type: none"> • <u>HER2-overexpressing biliary tract cancer</u> • <u>HER2-overexpressing cervical cancer</u> • <u>HER2-overexpressing colorectal cancer</u> • <u>HER2-overexpressing endometrial carcinoma</u> • <u>HER2-overexpressing occult primary</u> • <u>HER2-overexpressing ovarian cancer</u> • <u>HER2-overexpressing pancreatic adenocarcinoma</u> • <u>HER2-overexpressing small bowel adenocarcinoma</u> • <u>HER2-overexpressing urothelial carcinoma</u> • <u>HER2-overexpressing vaginal cancer</u> • <u>HER2-overexpressing vulvar cancer</u> <p>We apply the following limitations for charges of HCPCS code J9358:</p> <ul style="list-style-type: none"> • <u>No more than 675 units per date of service for providers with a specialty other than home infusion therapy or pharmacy</u> • <u>No more than 1,350 units per 6 weeks for providers with a specialty other than pharmacy</u> • <u>No more than 1,400 units per 6 weeks for providers with a specialty of pharmacy</u>
<u>Why is Humana making this change? / Change Reason:</u>	<p>The above limitations were established by the FDA-approved package insert and prescribing information and the pharmaceutical compendia.</p> <p>Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body weight that substantiates the medical necessity of the additional units.</p>
<u>Language:</u>	English
<u>Impacted Products:</u>	Medicaid- Louisiana